Moderna (MRNA)
51.59
0.00 (0.00%)
Upcoming Events
Latest Headlines
Form 144 Moderna, Inc. Filed by: Klinger Shannon Thyme
June 4, 2026 1:27 PM - SEC Filing
Form 4 Moderna, Inc. For: Jun 01 Filed by: Mock James M
June 3, 2026 4:22 PM - SEC Filing
Form 4 Moderna, Inc. For: Jun 01 Filed by: Klinger Shannon Thyme
June 3, 2026 4:19 PM - SEC Filing
Form 4 Moderna, Inc. For: Jun 01 Filed by: Hoge Stephen
June 3, 2026 4:16 PM - SEC Filing
Moderna (MRNA) sees strong intraday gains
June 3, 2026 2:14 PM - StreetInsider
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 3, 2026 8:30 AM - StreetInsider
Moderna to Present at Upcoming Conference in June 2026
June 2, 2026 7:01 AM - StreetInsider
Moderna and Merck report sustained melanoma treatment benefits at 5 years
June 1, 2026 8:01 AM - StreetInsider
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASC
June 1, 2026 8:01 AM - StreetInsider
Moderna receives $50 million from CEPI for Bundibugyo Ebola vaccine
June 1, 2026 5:49 AM - StreetInsider
Moderna and other groups get $60 million to develop Ebola vaccine
June 1, 2026 5:43 AM - StreetInsider
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
June 1, 2026 5:00 AM - StreetInsider
Form 4 Moderna, Inc. For: May 27 Filed by: Mock James M
May 29, 2026 5:13 PM - SEC Filing
Form 4 Moderna, Inc. For: May 27 Filed by: Klinger Shannon Thyme
May 29, 2026 5:10 PM - SEC Filing
Form 4 Moderna, Inc. For: May 27 Filed by: Hoge Stephen
May 29, 2026 5:05 PM - SEC Filing
UBS Reiterates Neutral Rating on Moderna (MRNA)
May 26, 2026 9:15 AM - StreetInsider
Form 4 Moderna, Inc. For: May 21 Filed by: AFEYAN NOUBAR
May 22, 2026 7:00 PM - SEC Filing
Form 144 Moderna, Inc. Filed by: Flagship Pioneering, LLC
May 21, 2026 3:07 PM - SEC Filing
Moderna (MRNA) call put ratio 14 calls to 1 put with a focus on May 22 weekly 52, 55 and 57 calls
May 21, 2026 2:06 PM - StreetInsider
JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms
May 20, 2026 3:10 PM - StreetInsider
JPMorgan Reinstates Moderna (MRNA) at Underweight
May 20, 2026 4:30 AM - StreetInsider
Form 4 Moderna, Inc. For: May 15 Filed by: Hoge Stephen
May 18, 2026 4:58 PM - SEC Filing
Colorado public health officials investigating hantavirus death not linked to cruise ship cluster - ABC
May 18, 2026 11:32 AM - StreetInsider
High School student in New York linked to suspected hantavirus case - Local report
May 15, 2026 12:55 PM - StreetInsider
Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism
May 15, 2026 10:15 AM - StreetInsider
Form 144 Moderna, Inc. Filed by: Hoge Stephen
May 15, 2026 9:47 AM - SEC Filing
No Cases Of Hantavirus Infection In The US - CDC
May 14, 2026 2:12 PM - StreetInsider
Moderna Recognized by TIME as One of the World's Most Impactful Companies
May 12, 2026 5:00 PM - StreetInsider
FDA Commissioner Marty Makary to step down - Politico
May 12, 2026 12:52 PM - StreetInsider
WHO expects additional cases of hantavirus, but no wider outbreak seen
May 12, 2026 12:06 PM - StreetInsider
Bernstein: 'Hantavirus boosting interest in Moderna (MRNA)'
May 12, 2026 8:42 AM - StreetInsider
1 Hantavirus Suspected Case In Nebraska Is Dual US-UK Citizen - Bloomberg
May 11, 2026 11:24 AM - StreetInsider
HHS downplays Hantavirus risk amid repatriation efforts
May 11, 2026 10:23 AM - StreetInsider
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026 8:30 AM - Globe NewsWire
Moderna shares jump 8% after U.S. national tests positive for hantavirus
May 11, 2026 6:53 AM - StreetInsider
Moderna (MRNA) call put ratio 7.4 calls to 1 put amid wide price movement
May 11, 2026 6:25 AM - StreetInsider
Stocks expected to have increasing option volume: CRCL PBR B CEG SPG HIMS MOS PLUG MNDY ASTS FOXA DELL MRNA
May 11, 2026 6:09 AM - StreetInsider
Form 8-K Moderna, Inc. For: May 06
May 11, 2026 6:06 AM - SEC Filing
Form 4 Moderna, Inc. For: May 06 Filed by: Rubenstein David M.
May 8, 2026 5:08 PM - SEC Filing
Form 4 Moderna, Inc. For: May 06 Filed by: Hussain Abbas
May 8, 2026 5:06 PM - SEC Filing
Form 4 Moderna, Inc. For: May 06 Filed by: Horning Sandra
May 8, 2026 5:04 PM - SEC Filing
Form 4 Moderna, Inc. For: May 06 Filed by: NABEL ELIZABETH G
May 8, 2026 5:02 PM - SEC Filing
Form 4 Moderna, Inc. For: May 06 Filed by: Nader Francois
May 8, 2026 5:00 PM - SEC Filing
Form 4 Moderna, Inc. For: May 06 Filed by: Tallett Elizabeth E
May 8, 2026 4:58 PM - SEC Filing
Form 4 Moderna, Inc. For: May 06 Filed by: AFEYAN NOUBAR
May 8, 2026 4:55 PM - SEC Filing
Moderna Is Working On Early-stage Hantavirus Vaccines - Bloomberg
May 8, 2026 12:26 PM - StreetInsider
Form 144 Moderna, Inc. Filed by: SAGAN PAUL
May 8, 2026 11:24 AM - SEC Filing
Moderna stock jumps 10% amid hantavirus outbreak concerns
May 7, 2026 10:21 AM - StreetInsider
Moderna flu vaccine shows superior efficacy in phase 3 study
May 6, 2026 5:16 PM - StreetInsider
Moderna flu vaccine data published in medical journal
May 6, 2026 5:16 PM - StreetInsider
Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
May 6, 2026 5:16 PM - StreetInsider
Form 4 Moderna, Inc. For: Apr 30 Filed by: Horning Sandra
May 4, 2026 5:39 PM - SEC Filing
Form 4 Moderna, Inc. For: Apr 30 Filed by: Rubenstein David M.
May 4, 2026 5:37 PM - SEC Filing
Form 4 Moderna, Inc. For: Apr 30 Filed by: Hussain Abbas
May 4, 2026 5:25 PM - SEC Filing
Form 4 Moderna, Inc. For: Apr 30 Filed by: NABEL ELIZABETH G
May 4, 2026 5:00 PM - SEC Filing
Form 4 Moderna, Inc. For: Apr 30 Filed by: Nader Francois
May 4, 2026 4:49 PM - SEC Filing
Form 4 Moderna, Inc. For: Apr 30 Filed by: Tallett Elizabeth E
May 4, 2026 4:44 PM - SEC Filing
Moderna (MRNA) PT Raised to $45 at UBS
May 4, 2026 9:32 AM - StreetInsider
Moderna (MRNA) PT Raised to $33 at Morgan Stanley
May 4, 2026 8:46 AM - StreetInsider
Moderna (MRNA) PT Raised to $38 at RBC Capital
May 4, 2026 8:26 AM - StreetInsider
Moderna (MRNA) PT Raised to $49 at Goldman Sachs
May 4, 2026 6:39 AM - StreetInsider
Form 10-Q Moderna, Inc. For: Mar 31
May 1, 2026 4:11 PM - SEC Filing
Moderna (MRNA) PT Raised to $38 at RBC Capital
May 1, 2026 12:25 PM - StreetInsider
Form 144 Moderna, Inc. Filed by: Hussain Abbas
May 1, 2026 11:45 AM - SEC Filing
Moderna (MRNA) PT Raised to $32 at BofA Securities
May 1, 2026 10:25 AM - StreetInsider
Form 8-K Moderna, Inc. For: May 01
May 1, 2026 9:25 AM - SEC Filing
Moderna beats revenue expectations despite wider loss
May 1, 2026 6:53 AM - StreetInsider
Moderna (MRNA) Misses Q1 EPS by $1.38, Beats on Revenue
May 1, 2026 6:37 AM - StreetInsider
Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates
May 1, 2026 6:35 AM - StreetInsider
Form SCHEDULE 13G Moderna, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 30, 2026 11:30 AM - SEC Filing
Moderna (MRNA) call put ratio 2 calls to 1 put with a focus on May 1 weekly 55 calls into quarter results
April 30, 2026 11:14 AM - StreetInsider
Moderna (MRNA) call put ratio 1 calls to 1 put with a focus on June options into quarter results
April 30, 2026 3:35 AM - StreetInsider
Moderna begins phase 3 trial of mRNA bird flu vaccine
April 21, 2026 7:01 PM - StreetInsider
Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate
April 21, 2026 7:01 PM - StreetInsider
Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting
April 21, 2026 10:00 AM - StreetInsider
Moderna receives EU approval for first flu-COVID combination vaccine
April 21, 2026 9:41 AM - StreetInsider
Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19
April 21, 2026 9:41 AM - StreetInsider
Moderna to Present at Upcoming Conferences in May 2026
April 21, 2026 7:01 AM - StreetInsider
Moderna presents melanoma therapy data showing 83% response rate
April 17, 2026 3:00 PM - StreetInsider
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026
April 17, 2026 3:00 PM - StreetInsider
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026
April 15, 2026 7:03 AM - StreetInsider
Moderna (MRNA) PT Raised to $35 at RBC Capital
April 7, 2026 9:03 AM - StreetInsider
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026
April 6, 2026 6:01 PM - StreetInsider
Form 4 Moderna, Inc. For: Apr 02 Filed by: Mock James M
April 6, 2026 4:46 PM - SEC Filing
Moderna (MRNA) PT Raised to $48 at Barclays
April 2, 2026 3:42 AM - StreetInsider
Form SCHEDULE 13G/A Moderna, Inc. Filed by: VANGUARD GROUP INC
March 27, 2026 10:51 AM - SEC Filing
Form DEF 14A Moderna, Inc. For: May 06
March 16, 2026 4:33 PM - SEC Filing
Form DEFA14A Moderna, Inc.
March 16, 2026 4:33 PM - SEC Filing
Form ARS Moderna, Inc. For: Dec 31
March 16, 2026 4:32 PM - SEC Filing
US Judge blocks Trump Admin cuts to number of routinely recommended vaccines for children - Reuters
March 16, 2026 3:46 PM - StreetInsider
US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports
March 11, 2026 6:32 AM - StreetInsider
Full Article List
